Eudora Wang
Eudora Wang is a Hong Kong-based reporter at DealStreetAsia, where she covers venture capital, private equity and technological advancements in the Greater China region. She was previously the chief reporter at China-focused bilingual news platform China Money Network.
Stories by Eudora Wang
A glance at the world’s unicorns: China overtakes US for the first time
Of a global tally of 494 unicorns, 206 are Chinese and 203 are American.
China’s cloud-based home decor firm Kujiale grabs unicorn tag with Series D+ funding
The round was led by Hillhouse Capital and joined by Shunwei Capital and GGV Capital.
China Digest: Tech startups Transwarp, Emotibot and Cloopen raise fresh funding
Big data platform Transwarp, human-robot interaction provider Emotibot and cloud communications service provider Cloopen have raised fresh funding.
Shunwei Capital backs Indian bike-taxi service Rapido’s $55m Series B round
WestBridge Capital, Alibaba-backed BAce Capital and existing Rapido investor Nexus Venture Partners also participated in the latest round.
China’s tight oversight on cross-border payment is good for all: Airwallex co-founder Lucy Liu
The Australia-based unicorn was recently removed from China's regulatory blacklist.
China Deal Monitor: Kids coding startup Hetao101 raises $50m and more updates
DealStreetAsia has put together a table listing out top VC deals in China on October 23, 2019.
Chinese O2O retailer KK Group enters unicorn club with $100m Series D round
The round was led by Alibaba co-founder Jack Ma-backed electronic World Trade Platform (eWTP).
HK-based Sandbox VR nabs $11m from A-listers Will Smith, Katy Perry & others
The investment comes nine months after it raised $68 million Series A from Alibaba, Andreesen Horowitz, and others.
China Deal Monitor: E-invoicing firm Ekuaibao raises $50m and more updates
DealStreetAsia has put together a table listing out prominent VC deals in China last week.
China’s 3SBio, Highlight Capital, Yonghua back $50m Verseau Therapeutics round
Verseau has a strategic collaboration with HK-listed 3SBio, a biotech company with biopharmaceutical franchises.
